Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BMO Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $68

BMO Capital analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $70 to $68.
byBenzinga Newsdesk
August 19, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

BMO Capital analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $70 to $68.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0